Antibiotic Administration Guidelines

Introduction to Cefepime Administration

• Cefepime is a fourth-generation cephalosporin with broad-spectrum activity, requiring multiple daily doses, typically administered 2-3 times daily (every 8-12 hours) depending on the infection being treated and patient factors, as recommended by various guideline societies 1, 2, 3
• The Intensive Care Medicine society recommends administering cefepime through prolonged intravenous infusion of 3-4 hours for severe infections, especially when there is a risk of pharmacodynamic failure or when bacteria have elevated MICs 4

Dosing and Administration

• For severe infections, the Intensive Care Medicine society suggests administering cefepime via prolonged infusion of 3-4 hours to improve pharmacodynamic exposure, especially in cases of deep-seated infections, bacteria with elevated MICs, and patients with significant pharmacokinetic changes 4
• The American College of Cardiology recommends 2g IV every 8 hours for serious infections, with a strength of evidence supporting this dosing regimen 3
• For prosthetic valve endocarditis, the guideline recommends 6g per day IV in 3 equally divided doses (2g every 8 hours), as supported by the American College of Cardiology and other guideline societies 1, 3
• The European Respiratory Society recommends 100-150 mg/kg/day in 2-3 divided doses (maximum 6g/day) for cystic fibrosis patients, with a moderate strength of evidence supporting this dosing regimen 2
• The following table summarizes the recommended dosing regimens for cefepime:

Renal Impairment Considerations

• Renal impairment requires dose adjustment, but cefepime is still typically given multiple times daily with extended intervals, as recommended by guideline societies 5
• The following table outlines the recommended dosing adjustments for patients with renal impairment:

4

Therapeutic Drug Monitoring and Resistance Prevention

• The Intensive Care Medicine society suggests that therapeutic drug monitoring (TDM) may be beneficial in critically ill patients to optimize dosing 4
• Prolonged or continuous infusion of antibiotics, such as cefepime, can prevent the emergence of bacterial resistance, particularly with certain strains (S. aureus, P. aeruginosa, Enterobacteriaceae) 4
• Monitoring local susceptibility patterns is crucial, as resistance can develop, and cefepime may be less effective against ESBL-producing organisms with elevated MICs, with a high strength of evidence supporting this concern 6
• Cefepime has excellent coverage against the HACEK group (when susceptible) and is effective against ESBL-producing Enterobacteriaceae, but carbapenems are generally preferred over cefepime, especially when cefepime MICs are elevated (4-8 μg/mL), as recommended by guideline societies 6, 1

Optimizing Efficacy

• For patients with severe infections, the Intensive Care Medicine society recommends maintaining higher plasma concentrations (Cmin/MIC >4-6) to optimize efficacy 4
• Beta-lactams like cefepime require maintaining concentrations above the MIC for at least 60-70% of the dosing interval for optimal bactericidal activity, which supports twice or three-times daily administration, as recommended by the Praxis Medical Insights guideline 5
• Extended infusions over 3-4 hours rather than bolus dosing may be recommended for serious infections to improve pharmacodynamic exposure, with a high strength of evidence supporting this approach 5
• Continuous infusion may be considered for critically ill patients with severe infections to optimize pharmacodynamic targets, as supported by the Praxis Medical Insights guideline 5
• Underdosing can occur with once-daily dosing due to cefepime's short half-life, leading to subtherapeutic levels for much of the day, with a high strength of evidence supporting this concern 5
• Dosing errors, such as underdosing for serious infections or resistant organisms, and failure to adjust for renal function, can lead to treatment failures, as warned by guideline societies 7